Xoma Halts Acne Therapy XMP.629 Development, Will Evaluate BPI Program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Xoma is evaluating all of its existing bactericidal/ permeability increasing protein (BPI) programs in the wake of "inconclusive" Phase II results for the acne treatment XMP.629, the company said.